# Sapphiros

Sapphiros is a Private Equity based in Boston, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Boston, United States
- **Region:** North America
- **Address:** 135 William T Morrissey Blvd, Suite P101, Boston, MA 02125, United States
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** sapphiros.com
- **LinkedIn:** https://www.linkedin.com/company/sapphiros

## Regulatory record

- **Reports private funds:** No

## About

Sapphiros is a privately held consumer diagnostics company backed by KKR and Neoenta. It brings together advanced science, intelligent design and scalable technology to make high-quality diagnostic testing accessible to all. Sapphiros was founded to close the gaps in health testing revealed during the Covid-19 pandemic. Its portfolio includes novel sample collection, next generation diagnostics, and extreme volume manufacturing.

## Sectors

- Digital Health
- Healthcare Services
- Diagnostics

## Offices

- Cambridge, United Kingdom
- Hove, United Kingdom
- Saffron Walden, United Kingdom

## People

- Namal Nawana — Founder
- Mark Gladwell — Chief Executive Officer, President & Board Member
- Dawn Hudson — Board Member
- Carrie Eglinton Manner — Board Member
- Ali Satvat — Board Member
- Anuv Ratan — Board Member
- Jackson McAdam — Chief Financial Officer
- Teresa Abraham — Vice President of Scientific & Technical Affairs
- Andy Garfield — Chief Operations Officer
- Hannah Slack — HR Director
- KC McGrath — Vice President, Product Strategy
- Ryan Schmidt — General Manager, Commercial
- Mike Robbat — General Counsel
- Peter Stebbins — Vice President and General Manager, Satio

## Questions

### What does Sapphiros actually own and operate?

Sapphiros operates four disclosed subsidiaries: Satio, developing a consumer wearable diagnostic patch; GrapheneDx, building a handheld at-home testing device; a Cambridge-based molecular-detection unit focused on isothermal nucleic-acid amplification; and a Hove-based materials and manufacturing center producing printed electronics and lateral-flow tests. The firm controls its own UK manufacturing lines rather than outsourcing production.

### Who runs Sapphiros, and who makes investment decisions?

Sapphiros does not publicly disclose its management team or investment committee on its website. Corporate filings show the US entity (Sapphiros LLC) and UK entity (Sapphiros UK Ltd) are registered but do not list directors or principals in publicly available materials. Decision-making structure is therefore unconfirmed from primary sources.

### Where does Sapphiros manufacture its diagnostics, and at what scale?

Manufacturing is concentrated at the Hove, UK facility, which is described as a center of excellence for extreme-volume lateral-flow production and printed electronics. The firm states the facility has a capacity of five billion units annually, making it one of the highest-volume diagnostics manufacturing sites publicly disclosed by a private platform.

### What types of diagnostics does Sapphiros focus on?

The portfolio spans consumer-based patch diagnostics (Satio), molecular at-home testing (GrapheneDx), ultra-rapid isothermal amplification for infectious disease and genetic testing (Cambridge), and lateral-flow and printed-electronics formats (Hove). The common thread is low-cost, scalable platforms intended for both advanced and resource-limited settings.

## Related profiles

- [SapphireInk Ventures](https://altss.com/profile/sapphireink-ventures)
- [Sapura](https://altss.com/profile/sapura)

---

Last updated: 2026-08-11T15:08:04.536Z

Canonical page: https://altss.com/profile/sapphiros

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology